The Medical Letter on Drugs and Therapeutics
Lumateperone (Caplyta) for Bipolar Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lumateperone (Caplyta) for Bipolar Depression
The oral second-generation antipsychotic drug lumateperone (Caplyta – Intra-Cellular Therapies), which was approved by the FDA in 2020 for treatment of schizophrenia, is now approved for use as monotherapy or as an adjunct to lithium or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lumateperone (Caplyta) for Bipolar Depression
Article code: 1656f
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.